FDA Pilots AI‑Enabled Real‑Time Clinical Trials with AstraZeneca and Amgen
What Happened – The U.S. Food and Drug Administration announced a pilot program that uses artificial‑intelligence and data‑science tools to run clinical trials in “real‑time,” allowing regulators to view safety and efficacy signals as they occur. Two proof‑of‑concept studies—AstraZeneca’s Phase 2 mantle‑cell lymphoma trial and Amgen’s Phase 1b small‑cell lung cancer trial—have already been initiated.
Why It Matters for TPRM –
- AI‑driven trial monitoring could reshape data‑handling practices for pharma sponsors, CROs, and research hospitals, creating new third‑party risk vectors.
- Real‑time data flows increase exposure to cloud‑based analytics platforms, raising concerns about data privacy, model integrity, and supply‑chain security.
- Early regulatory adoption may accelerate AI procurement cycles, prompting organizations to reassess vendor due‑diligence on AI/ML services.
Who Is Affected – Pharmaceutical manufacturers (AstraZeneca, Amgen), contract research organizations, academic medical centers (e.g., MD Anderson, University of Pennsylvania), AI/ML service providers, and any downstream vendors handling trial data.
Recommended Actions –
- Review contracts with AI/ML vendors for data‑security clauses, model‑validation requirements, and audit rights.
- Validate that cloud‑hosting partners implement “security‑by‑default” controls for PHI and trial data.
- Incorporate AI‑risk assessments into existing third‑party risk frameworks and monitor FDA guidance updates.
Technical Notes – The FDA has not disclosed the specific AI models or platforms used; however, the pilot relies on continuous data ingestion, real‑time analytics, and automated signal detection. Potential data types include electronic health records, lab results, imaging, and adverse‑event reports. Source: DataBreachToday